Loading clinical trials...
Loading clinical trials...
Phase 1 Randomized, Double-blind, Three Period, Crossover Study Comparing PD/PK, Safety and Tolerability Profiles for Arecor Ultra-rapid Insulin Aspart (AT247), NovoLog® and Fiasp® in Participants With T1DM During CSII
Conditions
Interventions
AT247
NovoLog
+1 more
Locations
1
United States
ProSciento, Inc
Chula Vista, California, United States
Start Date
January 3, 2022
Primary Completion Date
September 9, 2022
Completion Date
September 9, 2022
Last Updated
September 13, 2022
NCT06807190
NCT04786262
NCT06748963
NCT06329375
NCT06945406
NCT06325202
Lead Sponsor
Arecor Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions